Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
20.15
+0.10 (0.50%)
Dec 18, 2025, 2:39 PM EST - Market open
Innoviva Revenue
Innoviva had revenue of $107.80M in the quarter ending September 30, 2025, with 20.44% growth. This brings the company's revenue in the last twelve months to $388.52M, up 10.14% year-over-year. In the year 2024, Innoviva had annual revenue of $358.71M with 15.54% growth.
Revenue (ttm)
$388.52M
Revenue Growth
+10.14%
P/S Ratio
3.32
Revenue / Employee
$3,059,220
Employees
127
Market Cap
1.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 358.71M | 48.25M | 15.54% |
| Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
| Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
| Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
| Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
| Dec 31, 2019 | 261.02M | 12.00K | - |
| Dec 31, 2018 | 261.00M | 43.79M | 20.16% |
| Dec 31, 2017 | 217.22M | 83.65M | 62.63% |
| Dec 31, 2016 | 133.57M | 79.62M | 147.58% |
| Dec 31, 2015 | 53.95M | 45.52M | 539.74% |
| Dec 31, 2014 | 8.43M | 3.90M | 86.08% |
| Dec 31, 2013 | 4.53M | -1.08M | -19.26% |
| Dec 31, 2012 | 5.61M | -18.90M | -77.10% |
| Dec 31, 2011 | 24.51M | 289.00K | 1.19% |
| Dec 31, 2010 | 24.22M | -151.00K | -0.62% |
| Dec 31, 2009 | 24.37M | 1.28M | 5.53% |
| Dec 31, 2008 | 23.10M | 1.09M | 4.97% |
| Dec 31, 2007 | 22.00M | 2.42M | 12.33% |
| Dec 31, 2006 | 19.59M | 7.53M | 62.49% |
| Dec 31, 2005 | 12.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INVA News
- 5 days ago - U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - Business Wire
- 6 days ago - US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections - Reuters
- 6 days ago - Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - Business Wire
- 23 days ago - Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference - Business Wire
- 6 weeks ago - Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Antheia Appoints Eric d'Esparbes as Chief Financial Officer - PRNewsWire
- 2 months ago - Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 - Business Wire
- 2 months ago - Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 - Business Wire